RT Journal Article
SR Electronic
T1 Effectiveness of the BNT162b vaccine fourth dose in reducing SARS-CoV-2 infection among healthcare workers in Israel, a multi-center cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.11.22273327
DO 10.1101/2022.04.11.22273327
A1 Cohen, Matan J
A1 Oster, Yonatan
A1 Moses, Allon E
A1 Spitzer, Avishay
A1 Benenson, Shmuel
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/04/13/2022.04.11.22273327.abstract
AB During December 2021 the fifth COVID-19 wave started in Israel, caused mostly by the Omicron variant, affecting the unvaccinated and vaccinated population. Ninety percent of the Israeli adults, including most healthcare workers (HCWs), received three doses of the BNT162b2 vaccine until September 2021. Following the success and safety of the 3rd dose in preventing infection and severe disease, on December 30, 2021, the Israeli Ministry of Health recommended a voluntary 4th vaccine dose to adults above 60 years, immunocompromised, and HCWs. We compared breakthrough infections in HCWs, between 3 and 4-dose recipients.Hospitals collected data on personnel vaccinations and infections dates. The study cohort included all HCWs in eleven hospitals in Israel, who have been vaccinated with three doses up to September 30, 2021, and had not contracted COVID-19 before the vaccination campaign (January 2, 2022).We calculated breakthrough infection rates in 4-dose recipients (more than six days after vaccination) vs. 3-dose recipients. Rate-ratios were calculated for the entire cohort and for subgroups (hospital, sex, age-groups, and profession). Additionally, we repeated the calculations on 4-dose and 3-dose recipients who received the 3rd dose on the same date and were matched for sex, age group, profession and hospital. We generated time-dependent Cox-regression models to account for 4th dose administration timing (Supplement).There were 29,612 HCWs who received 3 vaccine doses between August and September 2021; of these, 5,331 (18.0%) received the 4th dose during January 2022 and were not infected by the first week after vaccination. Overall breakthrough infection rates in the 4-dose and 3-dose groups were 368/5331 (6.9%) and 4802/24280 (19.8%), respectively. The RR (95%CI) was 0.35 (0.32 to 0.39) for crude analysis, and 0.61 (0.54 to 0.71) in the matched analysis. The adjusted HR in the Cox-regression model was 0.56 (0.50 to 0.63). In both groups, severe disease and death were not reported.Our data shows that the 4th BNT162b2 dose resulted in reduced breakthrough infection rates among HCWs. This reduction, similar to the findings in the Israeli elderly population, is lower than that observed after the 3rd dose.Nevertheless, considering the high infectivity of the Omicron variant, which led to critical medical staff shortages, a 4th vaccine dose should be considered to mitigate the infection rate among HCWs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:1.Reviewed by the ethical review board, Bnei Zion Medical Center, Haifa, Israel, and ethical approval was given, need for consent was waived. 2.Reviewed by the ethical review board, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, and ethical approval was given, need for consent was waived. 3.Reviewed by the ethical review board, Edith Wolfson Medical Center, Holon, Israel, and ethical approval was given, need for consent was waived. 4.Reviewed by the ethical review board, Shaare-Zedek Medical Center, Jerusalem, Israel, and ethical approval was given, need for consent was waived. 5.Reviewed by the ethical review board, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, and ethical approval was given, need for consent was waived. 6.Reviewed by the ethical review board, Meir Medical Center, Kfar-Saba, Israel, and ethical approval was given, need for consent was waived. 7.Reviewed by the ethical review board, Kaplan Medical Center, Clalit Health Services, Israel, and ethical approval was given, need for consent was waived. 8.Reviewed by the ethical review board, Rambam Health Care Campus, Haifa, Israel, and ethical approval was given, need for consent was waived. 9.Reviewed by the ethical review board, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel, and ethical approval was given, need for consent was waived. 10.Reviewed by the ethical review board, Baruch Padeh Medical Center, Poriya, Israel, and ethical approval was given, need for consent was waived. 11.Reviewed by the ethical review board, Barzilai Medical Center, Ashkelon, Israel, and ethical approval was given, need for consent was waived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors